Home » Thought Leadership

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 134 posts
ISPOR International 2019: Cross-Country ICER Evolution: What Does it Now Mean to be Cost-Effective?
May 12, 2019 | Research posters

ISPOR International 2019: The Importance of Overall Survival as a Clinical Endpoint in FDA vs. EMA Regulatory Approval

ISPOR International 2019: CBPartners presented a poster about the importance of overall survival (OS) data as a clinical endpoint in FDA vs. EMA regulatory approval.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 9, 2019 | Videos

What is the role of ICER today and in the future?

US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers what they see the role of ICER being today, and becoming in the future.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 3, 2019 | Videos

What’s Keeping Payers Up at Night?

US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers which market access challenges are currently keeping them up at night.

May 1, 2019 | Blogs

Alzheimer’s Disease Clinical Trials: Where Do We Go Now?

PART II of CBPartners' CNS series:

April 25, 2019 | Blogs

Cell and Gene Therapies: Paving the Commercial Pathways of Tomorrow

While advanced therapies such as cell and gene therapy have disrupted the healthcare industry, there is much that is still unknown – as well the current appetite for such therapies will wane as their approvals become more common, and the budget implications become real. CBPartners' Cell and Gene Therapy Center of Excellence explores the short and long-term commercial outlook for cell and gene therapies.